We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Protein Linked to Destruction of Mitochondria in Huntington's Disease

By LabMedica International staff writers
Posted on 28 Sep 2016
Researchers studying the molecular mechanisms involved in Huntington's disease (HD) have identified a protein that binds to mutant huntingtin protein in the mitochondria of neurons, which results in destruction of the mitochondria and death of the nerve cells.

Huntington’s disease is caused by a dominant gene that encodes the huntingtin protein. More...
The 5' end of the HD gene has a sequence of three DNA bases, cytosine-adenine-guanine (CAG), coding for the amino acid glutamine that is repeated multiple times. Normal persons have a CAG repeat count of between seven and 35 repeats, while the mutated form of the gene has anywhere from 36 to 180 repeats. The mutant form of huntingtin is broken down into toxic peptides, which contribute to the pathology of the syndrome.

Investigators at Case Western Reserve University (Cleveland, OH, USA) have been searching for factors that interact with mutant huntingtin protein to better understand the initial steps of Huntington’s disease progression. To this end they conducted proteomic analyses, which identified valosin-containing protein (VCP) as a mutant huntingtin-binding protein on the mitochondria.

VCP is an ATPase enzyme present in all eukaryotes. Its main function is to segregate protein molecules from large cellular structures such as protein assemblies, organelle membranes, and chromatin, and thus facilitate the degradation of released polypeptides by the multi-subunit protease proteasome.

The investigators reported in the August 26, 2016, online edition of the journal Nature Communications that VCP was selectively translocated to the mitochondria, where it was bound to mutant huntingtin protein in various HD models. VCP accumulated in mitochondria elicited excessive mitophagy (degradation of the mitochondria) and caused neuronal cell death.

Blocking huntingtin/VCP mitochondrial interaction with a peptide, HV-3, abolished VCP translocation to the mitochondria, corrected excessive mitophagy, and reduced cell death in HD mouse- and patient-derived cells and HD transgenic mouse brains. Treatment with HV-3 reduced behavioral and neuropathological phenotypes of HD in both fragment- and full-length huntingtin transgenic mice. These findings demonstrated a causal role of mutant huntingtin-induced VCP mitochondrial accumulation in HD pathogenesis and suggested that the peptide HV-3 might be a useful tool for developing new therapeutics to treat HD.

“Because mitochondrial dysfunction has been proposed to play an important role in the pathogenesis of Huntington’s disease, we investigated the binding proteins of mutant huntingtin on mitochondria,” said senior author Dr. Xin Qi, assistant professor of physiology and biophysics at Case Western Reserve University. “We found that VCP is a key player in mitochondria-associated autophagy, a mitochondria self-eating process. Over-accumulation of VCP on mitochondria thus results in a great loss of mitochondria, which leads to neuronal cell death due to lack of energy supply.”

Related Links:
Case Western Reserve University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gastrointestinal Panel
Xpert® GI Panel
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.